Clinical Trial Update: Effect of Different Iloprost Doses on Symptoms in Systemic Sclerosis [Phase 2]

View source ↗

Summary

The Phase 2 trial evaluating different iloprost doses for systemic sclerosis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Sclerosis

Drugs mentioned

• Iloprost (iloprost)

Snippet

Sponsor: Charite University, Berlin, Germany | Conditions: Systemic Sclerosis | Phase 2 | Status: TERMINATED